<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ene70131" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">4612</journal-id><journal-id journal-id-type="pmc-domain">ejneurol</journal-id><journal-id journal-id-type="publisher-id">ENE</journal-id><journal-title-group><journal-title>European Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">1351-5101</issn><issn pub-type="epub">1468-1331</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11973926</article-id><article-id pub-id-type="pmcid-ver">PMC11973926.1</article-id><article-id pub-id-type="pmcaid">11973926</article-id><article-id pub-id-type="pmcaiid">11973926</article-id><article-id pub-id-type="pmid">40192262</article-id><article-id pub-id-type="doi">10.1111/ene.70131</article-id><article-id pub-id-type="publisher-id">ENE70131</article-id><article-id pub-id-type="other">EJoN-25-0489.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Stratifying Multiple Sclerosis Susceptibility Risk: The Role of <italic toggle="no">HLA&#8208;E*01</italic> and Infectious Mononucleosis in a Population Cohort</article-title></title-group><contrib-group><contrib id="ene70131-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Nova</surname><given-names initials="A">Andrea</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7258-1938</contrib-id><xref rid="ene70131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>andrea.nova01@universitadipavia.it</email></address></contrib><contrib id="ene70131-cr-0002" contrib-type="author"><name name-style="western"><surname>Gentilini</surname><given-names initials="D">Davide</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8391-0725</contrib-id><xref rid="ene70131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ene70131-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ene70131-cr-0003" contrib-type="author"><name name-style="western"><surname>Di Caprio</surname><given-names initials="G">Giovanni</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-1913-9897</contrib-id><xref rid="ene70131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ene70131-cr-0004" contrib-type="author"><name name-style="western"><surname>Bourguiba&#8208;Hachemi</surname><given-names initials="S">Sonia</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2452-2861</contrib-id><xref rid="ene70131-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ene70131-cr-0005" contrib-type="author"><name name-style="western"><surname>Vince</surname><given-names initials="N">Nicolas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3767-6210</contrib-id><xref rid="ene70131-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ene70131-cr-0006" contrib-type="author"><name name-style="western"><surname>Gourraud</surname><given-names initials="PA">Pierre&#8208;Antoine</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4176-8388</contrib-id><xref rid="ene70131-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ene70131-cr-0007" contrib-type="author"><name name-style="western"><surname>Bernardinelli</surname><given-names initials="L">Luisa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7551-6664</contrib-id><xref rid="ene70131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ene70131-cr-0008" contrib-type="author"><name name-style="western"><surname>Fazia</surname><given-names initials="T">Teresa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9577-8450</contrib-id><xref rid="ene70131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="ene70131-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Brain and Behavioral Sciences</named-content>
<institution>University of Pavia</institution>
<city>Pavia</city>
<country country="IT">Italy</country>
</aff><aff id="ene70131-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Bioinformatics and Statistical Genomic Unit</named-content>
<institution>IRCCS Istituto Auxologico Italiano</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="ene70131-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Center for Research in Transplantation and Translational Immunology, UMR 1064</named-content>
<institution>Nantes Universit&#233;, CHU Nantes, INSERM</institution>
<city>Nantes</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Andrea Nova (<email>andrea.nova01@universitadipavia.it</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>32</volume><issue seq="171">4</issue><issue-id pub-id-type="pmc-issue-id">485591</issue-id><issue-id pub-id-type="doi">10.1111/ene.v32.4</issue-id><elocation-id>e70131</elocation-id><history><date date-type="rev-recd"><day>14</day><month>3</month><year>2025</year></date><date date-type="received"><day>19</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-23 01:25:32.480"><day>23</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">European Journal of Neurology</italic> published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ENE-32-e70131.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ENE-32-e70131.pdf"/><abstract><title>ABSTRACT</title><sec id="ene70131-sec-0001"><title>Background</title><p>Epstein&#8211;Barr Virus (EBV) and its clinical manifestation, infectious mononucleosis (IM), are strongly linked to MS risk. A recent in&#160;vitro study suggests that <italic toggle="no">HLA&#8208;E*01:03</italic>, in contrast to <italic toggle="no">HLA&#8208;E*01:01</italic>, may protect against MS through more effective immune responses against EBV&#8208;infected B cells. However, the role of <italic toggle="no">HLA&#8208;E*01</italic> in MS remains unclear.</p></sec><sec id="ene70131-sec-0002"><title>Methods</title><p>We investigated if <italic toggle="no">HLA&#8208;E*01:01</italic> was significantly associated with higher MS risk in individuals with a history of IM diagnosis, using 487,144 individuals from the UK Biobank's cohort. We estimated the interaction between <italic toggle="no">HLA&#8208;E*01:01</italic> and IM using Cox proportional hazard models, adjusting for demographics, smoking, childhood body size, older siblings, and MS&#8208;related HLA alleles (e.g., <italic toggle="no">HLA&#8208;DRB1*15:01</italic>).</p></sec><sec id="ene70131-sec-0003"><title>Results</title><p>
<italic toggle="no">HLA&#8208;E*01:01</italic> allele alone was not significantly associated with IM or MS (<italic toggle="no">p</italic>&#8201;&gt;&#8201;0.05). However, a significant interaction between <italic toggle="no">HLA&#8208;E*01:01</italic> and IM history was observed in relation to MS risk (<italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001). Specifically, MS risk was significantly higher in both <italic toggle="no">HLA&#8208;E*01:01</italic> heterozygotes (HR&#8201;=&#8201;1.74 [95% CI: 1.36, 1.97], <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001) and homozygotes (HR&#8201;=&#8201;3.01 [95% CI: 1.81, 3.88], <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001) with IM history, compared to <italic toggle="no">HLA&#8208;E*01:03</italic> homozygotes<italic toggle="no">.</italic> Conversely, these associations were non&#8208;significant in individuals without IM history (<italic toggle="no">p</italic>&#8201;&gt;&#8201;0.05). The estimated proportion of the combined risk attributable to interaction effects was 40% in <italic toggle="no">HLA&#8208;E*01:01</italic> heterozygotes and 65% in <italic toggle="no">HLA&#8208;E*01:01</italic> homozygotes.</p></sec><sec id="ene70131-sec-0004"><title>Conclusions</title><p>
<italic toggle="no">HLA&#8208;E*01:01</italic> carriers diagnosed with IM are at significantly increased risk of MS, independently from other MS&#8208;related HLA alleles. This supports the hypothesis that <italic toggle="no">HLA&#8208;E*01:01</italic> may contribute to MS susceptibility due to weaker immune control over EBV infection. Incorporating <italic toggle="no">HLA&#8208;E*01:01</italic> into existing MHC&#8208;based MS risk models could then enhance personalized risk assessments in individuals with IM history.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ene70131-kwd-0001">EBV</kwd><kwd id="ene70131-kwd-0002">HLA</kwd><kwd id="ene70131-kwd-0003">MHC</kwd><kwd id="ene70131-kwd-0004">mononucleosis</kwd><kwd id="ene70131-kwd-0005">multiple sclerosis</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="9"/><word-count count="6200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.5 mode:remove_FC converted:22.04.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="ene70131-body-0001"><sec id="ene70131-sec-0005"><label>1</label><title>Introduction</title><p>Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system, influenced by genetic susceptibility, environmental exposures, and immune system interactions [<xref rid="ene70131-bib-0001" ref-type="bibr">1</xref>, <xref rid="ene70131-bib-0002" ref-type="bibr">2</xref>, <xref rid="ene70131-bib-0003" ref-type="bibr">3</xref>]. Epstein&#8211;Barr virus (EBV) infection is a key environmental trigger [<xref rid="ene70131-bib-0004" ref-type="bibr">4</xref>, <xref rid="ene70131-bib-0005" ref-type="bibr">5</xref>, <xref rid="ene70131-bib-0006" ref-type="bibr">6</xref>, <xref rid="ene70131-bib-0007" ref-type="bibr">7</xref>], with infectious mononucleosis (IM), its symptomatic manifestation, being strongly associated with increased MS risk [<xref rid="ene70131-bib-0008" ref-type="bibr">8</xref>, <xref rid="ene70131-bib-0009" ref-type="bibr">9</xref>]. However, given that EBV infects over 90% of the global adult population, yet only a fraction develops MS, it is likely that host genetics play a key role in determining disease susceptibility. In this context, several studies highlighted how the presence of the MS&#8208;deleterious allele <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> and the absence of the MS&#8208;protective <italic toggle="yes">HLA&#8208;A*02:01</italic> synergistically amplify MS risk in EBV&#8208;infected individuals with IM history [<xref rid="ene70131-bib-0010" ref-type="bibr">10</xref>, <xref rid="ene70131-bib-0011" ref-type="bibr">11</xref>, <xref rid="ene70131-bib-0012" ref-type="bibr">12</xref>].</p><p>More recently, attention has shifted to <italic toggle="yes">HLA&#8208;E</italic> polymorphisms and their influence on immune responses to EBV [<xref rid="ene70131-bib-0005" ref-type="bibr">5</xref>]. <italic toggle="yes">HLA&#8208;E</italic> is a non&#8208;classical HLA class I molecule with various functions in both innate and adaptive immunology, including natural killer cell modulation via interaction with the CD94/NKG2 receptors [<xref rid="ene70131-bib-0013" ref-type="bibr">13</xref>]. Unlike classical HLA class I genes, <italic toggle="yes">HLA&#8208;E</italic> polymorphism is low in frequency and occurs with two variants, <italic toggle="yes">HLA&#8208;E*01:01</italic> and <italic toggle="yes">HLA&#8208;E*01:03</italic>. In general, studies have shown that the predominant presence of the <italic toggle="yes">HLA&#8208;E*01:03</italic> allele can provide higher molecular expression of <italic toggle="yes">HLA&#8208;E</italic> at the cell surface than the <italic toggle="yes">HLA&#8208;E*01:01</italic> allele [<xref rid="ene70131-bib-0014" ref-type="bibr">14</xref>]. A recent study by Vietzen et&#160;al. [<xref rid="ene70131-bib-0005" ref-type="bibr">5</xref>] found the <italic toggle="yes">HLA&#8208;E*01:03/01:03</italic> genotype (homozygous) to be overrepresented in individuals with high Epstein&#8211;Barr nuclear antigen 1 (EBNA1) antibody levels who did not develop MS. Furthermore, an in&#160;vitro co&#8208;culture experiment showed that the <italic toggle="yes">HLA&#8208;E*01:03</italic> allele, in contrast to <italic toggle="yes">HLA&#8208;E*01:01</italic>, enhances immune control over EBV&#8208;infected B cells through potent HLA&#8208;E&#8208;restricted CD8+ T cell responses, potentially preventing MS&#8208;related autoimmune processes. However, given the complexity of the major histocompatibility complex (MHC) region and the emphasis on HLA genes relevant to transplantation, the role of <italic toggle="yes">HLA&#8208;E*01</italic> in MS risk remains largely unexplored. Notably, <italic toggle="yes">HLA&#8208;E*01</italic> has not been found to be associated with MS risk in genome&#8208;wide association studies (GWASs) [<xref rid="ene70131-bib-0015" ref-type="bibr">15</xref>]. Based on the findings by Vietzen et&#160;al. [<xref rid="ene70131-bib-0005" ref-type="bibr">5</xref>], we hypothesized that the association between <italic toggle="yes">HLA&#8208;E*01</italic> and MS risk may be modified by the presence of a significant immune response triggered by EBV, such as the occurrence of IM [<xref rid="ene70131-bib-0016" ref-type="bibr">16</xref>]. This could be due to the differing abilities of <italic toggle="yes">HLA&#8208;E*01:01</italic> and <italic toggle="yes">HLA&#8208;E*01:03</italic> to control EBV infection effectively. To investigate this hypothesis, we used data from the UK Biobank, a large population&#8208;based cohort, to examine whether <italic toggle="yes">HLA&#8208;E*01</italic> interacts with IM in modulating MS risk. IM diagnoses, obtained from medical records and self&#8208;reports, were used as a marker of a clinically symptomatic EBV infection. Time&#8208;to&#8208;event analyses were then performed considering <italic toggle="yes">HLA&#8208;E*01</italic> and IM exposure, as well as other MS&#8208;related HLA alleles (e.g., <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> and <italic toggle="yes">HLA&#8208;A*02:01</italic>) and key confounders such as smoking and childhood body size.</p><p>We aimed to evaluate (i) whether <italic toggle="yes">HLA&#8208;E*01</italic> is associated with IM risk, (ii) whether <italic toggle="yes">HLA&#8208;E*01</italic> influences MS risk, and (iii) whether <italic toggle="yes">HLA&#8208;E*01</italic> and IM interact to increase MS susceptibility independently of the interactions between IM and <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> and <italic toggle="yes">HLA&#8208;A*02:01</italic> alleles. In particular, point (iii) seeks to determine whether individuals carrying <italic toggle="yes">HLA&#8208;E*01:01</italic> and diagnosed with IM represent a subgroup with higher MS susceptibility. Understanding this interaction could offer new insights into the gene&#8211;environment mechanisms underlying MS development and help identify individuals at higher risk based on HLA genotypes and IM history.</p></sec><sec sec-type="methods" id="ene70131-sec-0006"><label>2</label><title>Methods</title><sec id="ene70131-sec-0007"><label>2.1</label><title>Institutional Review Board Approval</title><p>This is an observational study conducted using a population cohort identified within the UK Biobank (REC approval 11/NW/0382) [<xref rid="ene70131-bib-0017" ref-type="bibr">17</xref>]. All participants gave informed consent on Biobank registration and are free to withdraw from the study at any time, at which point their data are censored and cannot be included in further analyses.</p></sec><sec id="ene70131-sec-0008"><label>2.2</label><title>Data</title><p>The UK Biobank offers a comprehensive range of health&#8208;related phenotypes and genetic data collected from 502,354 individuals aged over 40&#8201;years, recruited between 2006 and 2010. The sample predominantly consists of English individuals of white ethnicity, who generally have better overall health and higher income compared to the general population [<xref rid="ene70131-bib-0018" ref-type="bibr">18</xref>].</p></sec><sec id="ene70131-sec-0009"><label>2.3</label><title>Genotypes</title><p>In the UK Biobank, genome&#8208;wide genotype data were collected on a large proportion of individuals in the cohort (&#8776;97%). Genotypes were imputed using computationally efficient methods combined with the Haplotype Reference Consortium (HRC) and UK10K haplotype resource, and quality control on genetic variants were subsequently performed [<xref rid="ene70131-bib-0019" ref-type="bibr">19</xref>]. HLA&#8208;E*01 was identified via the rs1264457 polymorphism, where the G allele (major) denoted the <italic toggle="yes">HLA&#8208;E*01:01</italic> variant, while the A allele (minor) denoted the <italic toggle="yes">HLA&#8208;E*01:03</italic> variant [<xref rid="ene70131-bib-0020" ref-type="bibr">20</xref>]. MS&#8208;risk HLA alleles <italic toggle="yes">HLA&#8208;DRB1*15:01</italic>, <italic toggle="yes">HLA&#8208;DRB1*03:01</italic>, <italic toggle="yes">HLA&#8208;DRB1*13:03</italic>, <italic toggle="yes">HLA&#8208;DRB1*08:01</italic>, <italic toggle="yes">HLA&#8208;DQA1*01:01</italic>, <italic toggle="yes">HLA&#8208;DQB1*03:01</italic>, <italic toggle="yes">HLA&#8208;DQB1*03:02</italic>, <italic toggle="yes">HLA&#8208;B*07:02</italic>, and MS&#8208;protective HLA alleles <italic toggle="yes">HLA&#8208;A*02:01</italic>, <italic toggle="yes">HLA&#8208;B*38:01</italic>, <italic toggle="yes">HLA&#8208;B*44:02</italic>, and <italic toggle="yes">HLA&#8208;B*55:01</italic> were obtained by the UK Biobank performing imputation using HLA*IMP:02 [<xref rid="ene70131-bib-0021" ref-type="bibr">21</xref>]. MS risk HLA alleles were coded according to the number of alleles (0, 1, 2), while MS&#8208;protective HLA alleles were coded based on presence/absence (0, 1) of the allele. Lastly, we retrieved the first four genetic principal components as calculated by the UK Biobank. We excluded from the analyses the 15,210 individuals missing genotype data, leaving 487,144 individuals with complete genotype data.</p></sec><sec id="ene70131-sec-0010"><label>2.4</label><title>Infectious Mononucleosis Diagnosis</title><p>All diagnoses of IM were classified using the International Classification of Disease 10th revision (ICD&#8208;10) B27 and were retrieved as the earliest diagnosis date reported among hospital admissions, primary care, death registries and self&#8208;report sources (see Table&#160;<xref rid="ene70131-supitem-0007" ref-type="supplementary-material">S1</xref> for further details). Self&#8208;reported IM diagnoses were retrieved by the UK Biobank at the time of recruitment asking the participants the following two interview questions. First, &#8220;Has a doctor ever told you that you have had any other serious medical conditions or disabilities?&#8221; (the &#8216;other&#8217; referring to cancer, which was discussed separately during the interview), and second, &#8216;In the touch screen you selected that you have been told by a doctor that you have other serious illnesses or disabilities, could you now tell me what they are?&#8217;. Therefore, IM diagnoses mainly related to cases with symptomatology severe enough to require medical attention. Using the diagnosis date, we were able to consider IM as a time&#8208;varying exposure along the follow up.</p></sec><sec id="ene70131-sec-0011"><label>2.5</label><title>Outcome</title><p>MS cases were defined according to the ICD&#8208;10 diagnosis code G35. The diagnosis date was retrieved as the earliest date from at least one source among hospital admissions, primary care, death registries, and self&#8208;report (see Table&#160;<xref rid="ene70131-supitem-0007" ref-type="supplementary-material">S1</xref> for further details). To better characterize the date of MS onset and hence avoid delayed MS diagnoses [<xref rid="ene70131-bib-0022" ref-type="bibr">22</xref>], we anticipated the date of MS diagnosis in case of an earlier diagnosis of: (i) demyelination (ICD&#8208;10: G36&#8208;G37), (ii) abnormal findings on diagnostic imaging of the central nervous system (ICD&#8208;10: R90), or (iii) the presence of other MS onset&#8208;related symptoms occurring in the 5&#8201;years prior to the MS diagnosis date, such as optic neuritis (ICD&#8208;10: H46) (see Data S2 for a complete list). Age at MS diagnosis was determined by subtracting the date of birth from the date of MS diagnosis.</p></sec><sec id="ene70131-sec-0012"><label>2.6</label><title>Confounders</title><p>We considered the following confounders, collected at the initial assessment visit, for the association between IM diagnosis and MS: sex, year of birth, ethnicity (white, non&#8208;white), place of birth, ever smoked on most or all days, childhood body size, having older siblings, and the first four genetic principal components. Using the age when the individual reported starting to smoke on most or all days, we were able to consider smoking as a time&#8208;varying exposure during the follow&#8208;up. UK Biobank data fields for each variable used in the analysis were provided in Table&#160;<xref rid="ene70131-supitem-0007" ref-type="supplementary-material">S2</xref>.</p></sec><sec id="ene70131-sec-0013"><label>2.7</label><title>Statistical Analysis</title><p>Descriptive statistics were calculated for all the analyzed variables, stratified by <italic toggle="yes">HLA&#8208;E*01</italic> genotype. Missing data for the confounding variables were imputed using multiple imputation [<xref rid="ene70131-bib-0023" ref-type="bibr">23</xref>] (see <xref rid="ene70131-supitem-0002" ref-type="supplementary-material">Supporting Information</xref>). We planned the following statistical analyses based on a retrospective cohort study design. In the first analysis, we evaluated the association between <italic toggle="yes">HLA&#8208;E*01</italic> and IM diagnosis using a time&#8208;to&#8208;event approach. Individuals were followed from birth to the first date among IM diagnosis or date of censoring, i.e., date of death, date of MS diagnosis, date of loss to follow&#8208;up, or date of follow&#8208;up end (31 December 2022). <italic toggle="yes">HLA&#8208;E*01</italic> was coded as a continuous variable according to the number of <italic toggle="yes">HLA&#8208;E*01:01</italic> alleles (0, 1, 2). We implemented a Cox proportional hazards (PHs) model with age as time scale, including <italic toggle="yes">HLA&#8208;E*01</italic> as the covariate of interest, and adjusted for the other MS&#8208;related HLA alleles, sex, year of birth, place of birth, ethnicity, having older siblings, and the first four genetic principal components. In the second analysis, using the same approach, we investigated the association between <italic toggle="yes">HLA&#8208;E*01</italic> and MS diagnosis. End of follow&#8208;up was defined based on the first date among MS diagnosis or date of censoring, i.e., date of death, date of loss to follow&#8208;up, or date of follow&#8208;up end. In the third analysis, we further investigated the associations between <italic toggle="yes">HLA&#8208;E*01</italic>, IM, and their interaction with MS diagnosis. To this aim, we considered IM diagnosis as a time&#8208;varying exposure by creating a variable coded as &#8220;No&#8221; for all individuals from the start of follow&#8208;up and changing to &#8220;Yes&#8221; from the time of IM diagnosis onward. In this analysis, we further adjusted for childhood body size and ever being a smoker (coded as a time&#8208;varying confounder). In a Cox PH model, we included multiplicative interaction terms between IM and, respectively, <italic toggle="yes">HLA&#8208;E*01</italic>, <italic toggle="yes">HLA&#8208;DRB1*15</italic>, and <italic toggle="yes">HLA&#8208;A*02</italic>. This method allows for adjustment for IM&#8208;specific effects on MS due to known interaction with <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> and <italic toggle="yes">HLA&#8208;A*02:01</italic> alleles. Using the Cox model's coefficient of the multiplicative interaction, we estimated the association between <italic toggle="yes">HLA&#8208;E*01:01</italic> allele and MS within subgroups of individuals with or without IM diagnosis, as well as the association between IM and MS within <italic toggle="yes">HLA&#8208;E*01</italic> genotype (see <xref rid="ene70131-supitem-0002" ref-type="supplementary-material">Supporting Information</xref>). Inspection of Schoenfeld residuals was conducted to assess the validity of the PH assumption, adjusting for any significant deviation including a stratification factor or using time&#8208;varying coefficients.</p><p>We also estimated interactions between <italic toggle="yes">HLA&#8208;E*01:01</italic> allele and IM diagnosis on the additive scale, calculating the Relative Excess Risk due to Interaction (RERI) and the Attributable Proportion due to interaction (AP) (see <xref rid="ene70131-supitem-0002" ref-type="supplementary-material">Supporting Information</xref>). Additive interactions further help to assess if MS tends to occur only if both <italic toggle="yes">HLA&#8208;E*01:01</italic> allele and IM diagnosis are present but not if just one or the other is present, suggesting a potential biological interaction [<xref rid="ene70131-bib-0024" ref-type="bibr">24</xref>, <xref rid="ene70131-bib-0025" ref-type="bibr">25</xref>]. We obtained 95% confidence intervals (CIs) for both multiplicative and additive interactions, implementing bootstrap sampling with replacement over 5000 replications and using the bias&#8208;corrected accelerated method [<xref rid="ene70131-bib-0026" ref-type="bibr">26</xref>]. We provided two&#8208;sided p&#8208;values derived from 95% bootstrap CIs using the R package <italic toggle="yes">boot.pval</italic>, considering <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 as statistically significant.</p></sec><sec id="ene70131-sec-0014"><label>2.8</label><title>Sensitivity Analyses</title><p>In the first sensitivity analysis, we evaluated if the strength of the interactions between <italic toggle="yes">HLA&#8208;E*01</italic> and IM diagnosis changed when excluding MS diagnoses over 50&#8201;years of age, i.e., late&#8208;onset MS (LOMS) cases&#160;[<xref rid="ene70131-bib-0027" ref-type="bibr">27</xref>]. Individuals were followed up to the first date among MS diagnosis or date of censoring, i.e., date of death, date of loss to follow&#8208;up, or date when the individuals reached 50&#8201;years of age. Similarly, in the second sensitivity analysis, we evaluated if the strengths of these interactions changed when excluding individuals born outside the UK (England, Wales, and Scotland).</p><p>Analyses were performed using RStudio 2023.06.1, and R code used for the main analysis was included in the <xref rid="ene70131-supitem-0002" ref-type="supplementary-material">Supporting Information</xref>.</p></sec></sec><sec sec-type="results" id="ene70131-sec-0015"><label>3</label><title>Results</title><sec id="ene70131-sec-0016"><label>3.1</label><title>Descriptive Statistics</title><p>We analyzed a sample of 487,144 individuals. During the follow&#8208;up period (median: 70&#8201;years, interquartile range (IQR): 64; 77), 3855 individuals (0.8%) had a diagnosis of IM and 2491 (0.5%) had a diagnosis of MS. The median age of IM diagnosis was 20&#8201;years (IQR: 17; 30), while the median age of MS diagnosis was 44&#8201;years (IQR: 36; 53). The discrepancy between this and the known average age at MS onset (&#8776;33&#8201;years) [<xref rid="ene70131-bib-0028" ref-type="bibr">28</xref>] derives from the cohort's demographic structure, which included individuals born between 1934 and 1971. As the cohort aged, the absence of younger individuals born after 1971 limited the inclusion of newly diagnosed younger cases, while LOMS cases (&gt;&#8201;50&#8201;years), whose incidence has been rising in recent years [<xref rid="ene70131-bib-0022" ref-type="bibr">22</xref>, <xref rid="ene70131-bib-0028" ref-type="bibr">28</xref>, <xref rid="ene70131-bib-0029" ref-type="bibr">29</xref>], disproportionately influenced the mean age at diagnosis at the end of follow&#8208;up (2022).</p><p>Demographic characteristics of the overall sample and stratified by <italic toggle="yes">HLA&#8208;E*01</italic> genotypes are reported in Table&#160;<xref rid="ene70131-tbl-0001" ref-type="table">1</xref>. 78,165 individuals (16%) carried the <italic toggle="yes">HLA&#8208;E*01:03/01:03</italic> genotype, 233,129 (48%) carried the HLA&#8208;E*01:01/01:03 genotype, and 175,850 (36%) carried the <italic toggle="yes">HLA&#8208;E*01:01/01:01</italic> genotype. Overall, individuals in the sample were more frequently females, of white ethnicity, born in England around 1950, had more frequently older siblings, and were less frequently smokers. These characteristics were nearly identical across <italic toggle="yes">HLA&#8208;E*01</italic> genotypes, while some imbalances can be found in other HLA alleles, i.e., a higher homozygotes' proportion of <italic toggle="yes">HLA&#8208;DRB1*15:01</italic>, <italic toggle="yes">HLA&#8208;A*02:01</italic>, <italic toggle="yes">HLA&#8208;DQB1*03:02</italic>, and <italic toggle="yes">HLA&#8208;B*07:02</italic> in individuals carrying the <italic toggle="yes">HLA&#8208;E*01:03/01:03</italic> genotype, and a higher homozygotes' proportion of <italic toggle="yes">HLA&#8208;DRB1*03:01</italic> and <italic toggle="yes">HLA&#8208;B*04:02</italic> in individuals carrying the <italic toggle="yes">HLA&#8208;E*01:01/01:01</italic> genotype.</p><table-wrap position="float" id="ene70131-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Descriptive statistics for analyzed variables for the overall sample and stratified by HLA&#8208;E*01 genotype.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">HLA&#8208;E*01:03/01:03</th><th align="center" valign="bottom" rowspan="1" colspan="1">HLA&#8208;E*01:01/01:03</th><th align="center" valign="bottom" rowspan="1" colspan="1">HLA&#8208;E*01:01/01:01</th><th align="center" valign="bottom" rowspan="1" colspan="1">Overall</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;78,165)</td><td align="center" valign="top" rowspan="1" colspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;233,129)</td><td align="center" valign="top" rowspan="1" colspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;175,850)</td><td align="center" valign="top" rowspan="1" colspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;487,144)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>Multiple sclerosis diagnosis</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">380 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">1191 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">920 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2491 (0.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">77,785 (99.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">231,938 (99.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">174,930 (99.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">484,653 (99.5%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>Age at multiple sclerosis diagnosis</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">43.2 [35.5, 50.6]</td><td align="center" valign="top" rowspan="1" colspan="1">44.9 [36.0, 54.0]</td><td align="center" valign="top" rowspan="1" colspan="1">44.2 [35.9, 53.4]</td><td align="center" valign="top" rowspan="1" colspan="1">44.2 [35.8, 53.3]</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>Infectious mononucleosis diagnosis</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">609 (0.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1901 (0.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1345 (0.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">3855 (0.8%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">77,556 (99.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">231,228 (99.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">174,505 (99.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">483,289 (99.2%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>Age at infectious mononucleosis diagnosis</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">20.3 [16.5, 28.7]</td><td align="center" valign="top" rowspan="1" colspan="1">20.4 [16.5, 29.5]</td><td align="center" valign="top" rowspan="1" colspan="1">20.2 [16.5, 29.8]</td><td align="center" valign="top" rowspan="1" colspan="1">20.3 [16.5, 29.5]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Females</td><td align="center" valign="top" rowspan="1" colspan="1">42,696 (54.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">126,348 (54.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">95,083 (54.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">264,127 (54.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Males</td><td align="center" valign="top" rowspan="1" colspan="1">35,469 (45.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">106,781 (45.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">80,767 (45.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">223,017 (45.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Year of birth</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">1950 [1945, 1958]</td><td align="center" valign="top" rowspan="1" colspan="1">1950 [1945, 1958]</td><td align="center" valign="top" rowspan="1" colspan="1">1950 [1945, 1958]</td><td align="center" valign="top" rowspan="1" colspan="1">1950 [1945, 1958]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Ethnicity</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#8208;White</td><td align="center" valign="top" rowspan="1" colspan="1">3819 (4.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">9563 (4.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">6510 (3.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">19,892 (4.1%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">72,425 (92.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">219,693 (94.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">166,982 (95.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">459,100 (94.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">1921 (2.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">3873 (1.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">2358 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">8152 (1.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Place of birth</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Africa</td><td align="center" valign="top" rowspan="1" colspan="1">1789 (2.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">4504 (1.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">3197 (1.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">9490 (1.9%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">America</td><td align="center" valign="top" rowspan="1" colspan="1">1122 (1.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">3248 (1.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">2202 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">6572 (1.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asia/Oceania</td><td align="center" valign="top" rowspan="1" colspan="1">2752 (3.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">6208 (2.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">3915 (2.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">12,875 (2.6%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">England</td><td align="center" valign="top" rowspan="1" colspan="1">60,855 (77.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">181,852 (78.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">136,361 (77.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">379,068 (77.8%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Europe</td><td align="center" valign="top" rowspan="1" colspan="1">1813 (2.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">4661 (2.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">2805 (1.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">9279 (1.9%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ireland/North Ireland</td><td align="center" valign="top" rowspan="1" colspan="1">1011 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">3512 (1.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">3249 (1.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">7772 (1.6%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Scotland</td><td align="center" valign="top" rowspan="1" colspan="1">5567 (7.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">18,214 (7.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">15,342 (8.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">39,123 (8.0%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Wales</td><td align="center" valign="top" rowspan="1" colspan="1">2974 (3.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">10,258 (4.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">8331 (4.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">21,563 (4.4%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">282 (0.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">672 (0.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">448 (0.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">1402 (0.3%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>Have older siblings</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">21,243 (27.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">63,743 (27.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">47,357 (26.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">132,343 (27.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">55,698 (71.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">165,908 (71.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">125,909 (71.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">347,515 (71.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">1224 (1.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">3478 (1.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2584 (1.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">7286 (1.5%)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Childhood body size at age 10</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thinner</td><td align="center" valign="top" rowspan="1" colspan="1">25,596 (32.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">76,107 (32.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">57,166 (32.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">158,869 (32.6%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Average</td><td align="center" valign="top" rowspan="1" colspan="1">38,975 (49.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">115,786 (49.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">87,611 (49.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">242,372 (49.8%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Plumper</td><td align="center" valign="top" rowspan="1" colspan="1">11,827 (15.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">36,342 (15.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">27,456 (15.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">75,625 (15.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">1767 (2.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">4894 (2.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">3617 (2.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">10,278 (2.1%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>Ever smoked on most or all days</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">42,627 (54.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">126,747 (54.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">95,919 (54.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">265,293 (54.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">35,094 (44.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">105,185 (45.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">79,070 (45.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">219,349 (45.0%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">444 (0.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">1197 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">861 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2502 (0.5%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;DRB1*15:01</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">53,112 (67.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">169,816 (72.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">137,809 (78.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">360,737 (74.1%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">22,497 (28.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">58,342 (25.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">35,718 (20.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">116,557 (23.9%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">2556 (3.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">4971 (2.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">2323 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">9850 (2.0%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;A*02:01</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">40,069 (51.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">125,559 (53.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">99,927 (56.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">265,555 (54.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">31,517 (40.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">90,694 (38.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">64,824 (36.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">187,035 (38.4%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">6579 (8.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">16,876 (7.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">11,099 (6.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">34,554 (7.1%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;DRB1*13:03</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">76,771 (98.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">228,949 (98.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">172,719 (98.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">478,439 (98.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">1388 (1.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">4161 (1.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">3106 (1.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">8655 (1.8%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">6 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (0.0%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;DRB1*08:01</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">75,278 (96.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">224,899 (96.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">170,026 (96.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">470,203 (96.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">2859 (3.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">8150 (3.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">5761 (3.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">16,770 (3.4%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">28 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">63 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">171 (0.0%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;DQA1*01:01</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">57,447 (73.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">171,528 (73.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">129,811 (73.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">358,786 (73.7%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">18,991 (24.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">56,916 (24.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">42,488 (24.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">118,395 (24.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">1727 (2.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">4685 (2.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">3551 (2.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">9963 (2.0%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;DQB1*03:01</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">54,331 (69.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">159,088 (68.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">117,196 (66.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">330,615 (67.9%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">21,593 (27.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">66,974 (28.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">52,484 (29.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">141,051 (29.0%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">2241 (2.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">7067 (3.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">6170 (3.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">15,478 (3.2%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;DRB1*03:01</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">67,476 (86.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">174,939 (75.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">114,725 (65.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">357,140 (73.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">10,264 (13.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">54,874 (23.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">54,388 (30.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">119,526 (24.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">425 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">3316 (1.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">6737 (3.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">10,478 (2.2%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;DQB1*03:02</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">58,536 (74.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">185,623 (79.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">149,816 (85.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">393,975 (80.9%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">18,179 (23.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">45,003 (19.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">24,935 (14.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">88,117 (18.1%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">1450 (1.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">2503 (1.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">1099 (0.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">5052 (1.0%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;B*38:01</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">75,804 (97.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">228,343 (97.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">174,149 (99.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">478,296 (98.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">2294 (2.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">4733 (2.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">1696 (1.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">8723 (1.8%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">67 (0.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">53 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">125 (0.0%)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>HLA&#8208;B*04:02</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">71,915 (92.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">190,524 (81.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">127,969 (72.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">390,408 (80.1%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">6113 (7.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">41,113 (17.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">43,833 (24.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">91,059 (18.7%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">137 (0.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">1492 (0.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">4048 (2.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">5677 (1.2%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HLA&#8208;B*55:01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">76,741 (98.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">225,689 (96.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">167,685 (95.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">470,115 (96.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">1415 (1.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">7391 (3.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">8042 (4.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">16,848 (3.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">9 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">123 (0.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">181 (0.0%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HLA&#8208;B*07:02</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">47,958 (61.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">165,341 (70.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">146,003 (83.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">359,302 (73.8%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heterozygote</td><td align="center" valign="top" rowspan="1" colspan="1">26,202 (33.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">63,098 (27.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">28,432 (16.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">117,732 (24.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Homozygote</td><td align="center" valign="top" rowspan="1" colspan="1">4005 (5.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">4690 (2.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">1415 (0.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">10,110 (2.1%)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Genetic principal component 1</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;12.0 [&#8722;13.3, &#8722;10.6]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;12.2 [&#8722;13.3, &#8722;10.8]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;12.2 [&#8722;13.4, &#8722;10.9]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;12.2 [&#8722;13.3, &#8722;10.8]</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Genetic principal component 2</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">3.6 [2.4, 4.8]</td><td align="center" valign="top" rowspan="1" colspan="1">3.7 [2.5, 4.8]</td><td align="center" valign="top" rowspan="1" colspan="1">3.7 [2.5, 4.8]</td><td align="center" valign="top" rowspan="1" colspan="1">3.7 [2.4, 4.8]</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Genetic principal component 3</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.5 [&#8722;2.7, &#8722;0.2]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.5 [&#8722;2.7, 98.8]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.5 [&#8722;2.7, &#8722;0.3]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.5 [&#8722;2.7, &#8722;0.2]</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Genetic principal component 4</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">1.0 [&#8722;1.2, 3.3]</td><td align="center" valign="top" rowspan="1" colspan="1">1.2 [&#8722;0.9, 3.5]</td><td align="center" valign="top" rowspan="1" colspan="1">1.4 [&#8722;0.8, 3.8]</td><td align="center" valign="top" rowspan="1" colspan="1">1.2 [&#8722;0.9, 3.6]</td></tr></tbody></table><table-wrap-foot id="ene70131-ntgp-0001"><fn id="ene70131-note-0001"><p>
<italic toggle="yes">Note:</italic> Median and interquartile range (IQR) was reported for continuous variables, while absolute and relative frequencies were reported for categorical variables.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ene70131-sec-0017"><label>3.2</label><title>Association Between <italic toggle="no">
<styled-content style="fixed-case" toggle="no">HLA</styled-content>&#8208;E*01:01</italic> and <styled-content style="fixed-case" toggle="no">IM</styled-content> Diagnosis</title><p>We first assessed the association between <italic toggle="yes">HLA&#8208;E*01</italic> and the risk of IM diagnosis using a Cox model adjusted for demographic and genetic covariates, finding no statistically significant association (HR&#8201;=&#8201;0.99 [95% CI: 0.94, 1.03], <italic toggle="yes">p</italic>&#8201;=&#8201;0.56).</p></sec><sec id="ene70131-sec-0018"><label>3.3</label><title>Association Between <italic toggle="no">
<styled-content style="fixed-case" toggle="no">HLA</styled-content>&#8208;E*01:01</italic> and <styled-content style="fixed-case" toggle="no">MS</styled-content> Diagnosis Stratified by <styled-content style="fixed-case" toggle="no">IM</styled-content> Diagnosis</title><p>In the second analysis, we assessed the association between <italic toggle="yes">HLA&#8208;E*01:01</italic> and the risk of MS diagnosis, adjusting for the same covariates. Since the association between <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> and MS risk violated the PH assumption (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), we estimated separate HRs for ages &#8804;&#8201;30 and&#8201;&gt;&#8201;30 (this threshold was chosen based on the Schoenfeld residuals plot shown in Figure&#160;<xref rid="ene70131-supitem-0004" ref-type="supplementary-material">S1</xref>, where HR decreases as age progresses and stabilizes around the age of 30). The Cox model revealed no statistically significant association between <italic toggle="yes">HLA&#8208;E*01:01</italic> and MS risk (HR&#8201;=&#8201;1.06 [95% CI: 0.99, 1.13], <italic toggle="yes">p</italic>&#8201;=&#8201;0.055).</p><p>We then included in the model the IM diagnosis as a time&#8208;varying covariate along with its interaction terms with <italic toggle="yes">HLA&#8208;E*01:01</italic>, <italic toggle="yes">HLA&#8208;DRB1*15:01</italic>, and lack of <italic toggle="yes">HLA&#8208;A*02:01</italic> allele. The model was further adjusted for childhood body size and smoking. The results highlighted a statistically significant interaction between <italic toggle="yes">HLA&#8208;E*01:01</italic> allele and IM diagnosis (<italic toggle="yes">&#946;</italic>&#8201;=&#8201;0.50, [95% CI: 0.27; 0.66], <italic toggle="yes">p</italic>&#8208;value &lt;&#8201;0.001), implying that the associations between each factor with MS varied depending on the levels of the other. Specifically, in individuals without IM diagnosis, <italic toggle="yes">HLA&#8208;E*01:01</italic> was not significantly associated with MS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.051). Conversely, in individuals with IM diagnosis, MS risk significantly increased by 74% in heterozygotes (<italic toggle="yes">HLA&#8208;E*01:01/01:03</italic>) and 301% in homozygotes (<italic toggle="yes">HLA&#8208;E*01:01/01:01</italic>) (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (see Table&#160;<xref rid="ene70131-tbl-0002" ref-type="table">2</xref> for HRs and 95% CIs). In line with previous findings [<xref rid="ene70131-bib-0010" ref-type="bibr">10</xref>, <xref rid="ene70131-bib-0011" ref-type="bibr">11</xref>, <xref rid="ene70131-bib-0012" ref-type="bibr">12</xref>], the Cox model also highlighted a statistically significant interaction between <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> allele and IM diagnosis (but not between the absence of <italic toggle="yes">HLA&#8208;A*02:01</italic> allele and IM diagnosis). This highlights how <italic toggle="yes">HLA&#8208;E*01:01</italic> alleles further increase MS risk through their interaction with IM independently from the interaction already taking place between IM and <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> alleles. Associations between IM diagnosis and MS given different combinations of <italic toggle="yes">HLA&#8208;E*01:01</italic> and <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> alleles were fully described in <xref rid="ene70131-supitem-0002" ref-type="supplementary-material">Supporting Information</xref> and reported in Figure&#160;<xref rid="ene70131-supitem-0005" ref-type="supplementary-material">S2</xref> and Table&#160;<xref rid="ene70131-supitem-0007" ref-type="supplementary-material">S3</xref>.</p><table-wrap position="float" id="ene70131-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Associations between HLA&#8208;E*01 genotype and Multiple Sclerosis diagnosis in individuals without or with a history of Infectious Mononucleosis diagnosis based on a Cox model including the interaction between HLA&#8208;E*01 and Infectious Mononucleosis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">HR [95% CI]</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Without IM diagnosis</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA&#8208;E*01:03/01:03</td><td align="center" colspan="2" valign="top" rowspan="1">Reference</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA&#8208;E*01:01/01:03</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 [0.99, 1.08]</td><td align="center" rowspan="2" valign="top" colspan="1">0.051</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA&#8208;E*01:01/01:01</td><td align="center" valign="top" rowspan="1" colspan="1">1.11 [0.99, 1.17]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>With IM diagnosis</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA&#8208;E*01:03/01:03</td><td align="center" colspan="2" valign="top" rowspan="1">Reference</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA&#8208;E*01:01/01:03</td><td align="center" valign="top" rowspan="1" colspan="1">1.74 [1.36, 1.97]</td><td align="center" rowspan="2" valign="top" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA&#8208;E*01:01/01:01</td><td align="center" valign="top" rowspan="1" colspan="1">3.01 [1.81, 3.88]</td></tr></tbody></table><table-wrap-foot id="ene70131-ntgp-0002"><fn id="ene70131-note-0002"><p>Abbreviations: 95% CI, 95% Confidence Interval obtained using bootstrap bias&#8208;corrected accelerated method; HR, Hazard Ratio; IM, Infectious Mononucleosis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ene70131-sec-0019"><label>3.4</label><title>Additive Interactions Between <styled-content style="fixed-case" toggle="no">IM</styled-content> Diagnosis and <italic toggle="no">
<styled-content style="fixed-case" toggle="no">HLA</styled-content>&#8208;E*01:01</italic>
</title><p>We also calculated interactions on the additive scale between <italic toggle="yes">HLA&#8208;E*01:01</italic> allele and IM diagnosis through the RERI and AP, with results reported in Table&#160;<xref rid="ene70131-supitem-0007" ref-type="supplementary-material">S4</xref> and depicted in Figure&#160;<xref rid="ene70131-supitem-0006" ref-type="supplementary-material">S3</xref>. Results showed statistically significant additive interactions between <italic toggle="yes">HLA&#8208;E*01:01</italic> and IM diagnosis in increasing MS risk for any given combination of <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> and <italic toggle="yes">HLA&#8208;A*02:01</italic> alleles (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), with an estimated AP&#8201;&#8776;&#8201;40% in <italic toggle="yes">HLA&#8208;E*01:01</italic> heterozygotes and &#8776;&#8201;65% in <italic toggle="yes">HLA&#8208;E*01:01</italic> homozygotes (see <xref rid="ene70131-supitem-0002" ref-type="supplementary-material">Supporting Information</xref> for further details).</p></sec><sec id="ene70131-sec-0020"><label>3.5</label><title>Sensitivity Analyses</title><p>In the first sensitivity analysis, we censored the follow&#8208;up up to 50&#8201;years of age to exclude 761 LOMS cases. In the second sensitivity analysis, we excluded 46,870 individuals born outside the UK. The results for both multiplicative and additive interactions between <italic toggle="yes">HLA&#8208;E*01</italic> and IM diagnosis were very similar to those in the main analysis. Multiplicative interactions were, respectively, <italic toggle="yes">&#946;</italic>&#8201;=&#8201;0.57 [95% CI: 0.28; 0.83] (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and <italic toggle="yes">&#946;</italic>&#8201;=&#8201;0.46 [95% CI: 0.24; 0.65] (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), while additive interactions were reported in Table&#160;<xref rid="ene70131-supitem-0007" ref-type="supplementary-material">S5</xref>.</p></sec></sec><sec sec-type="discussion" id="ene70131-sec-0021"><label>4</label><title>Discussion</title><p>Our study investigated the link between <italic toggle="yes">HLA&#8208;E*01</italic> polymorphisms, a history of IM diagnosis (a clinical manifestation of EBV infection) and MS risk, using data from 487,144 individuals in the UK Biobank. Previous research suggested that the <italic toggle="yes">HLA&#8208;E*01:03</italic> allele, compared to <italic toggle="yes">HLA&#8208;E*01:01</italic>, enhances immune activation against EBV&#8208;infected B cells, potentially protecting against MS [<xref rid="ene70131-bib-0005" ref-type="bibr">5</xref>]. However, GWASs have not identified a significant association between the <italic toggle="yes">HLA&#8208;E*01</italic> genotype and MS risk. Based on these insights, our study aimed to provide further investigation by using a statistical approach in a real&#8208;world data setting. Specifically, we aimed to investigate whether <italic toggle="yes">HLA&#8208;E*01:01</italic> is linked to an increased risk of MS following the occurrence of an IM diagnosis, potentially due to the previously mentioned weaker immune control against EBV&#8208;infected B cells [<xref rid="ene70131-bib-0005" ref-type="bibr">5</xref>].</p><p>Our findings indicate that <italic toggle="yes">HLA&#8208;E*01:01</italic> alone is not associated with an increased risk of MS or IM. Instead, when IM was diagnosed, individuals carrying the <italic toggle="yes">HLA&#8208;E*01:01</italic> allele had a significantly increased MS risk, with a proportion of combined risk attributable to interaction effects between <italic toggle="yes">HLA&#8208;E*01:01</italic> and IM estimated around 40% in heterozygotes and 65% in homozygotes [<xref rid="ene70131-bib-0030" ref-type="bibr">30</xref>]. The result supports our hypothesis, as it suggests a biologically relevant interaction between IM and <italic toggle="yes">HLA&#8208;E*01:01</italic>, where the genetic variant predisposes to MS. Importantly, the interaction between IM and <italic toggle="yes">HLA&#8208;E*01:01</italic> in increasing MS risk acts independently from the interaction between IM diagnosis and <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> (a well&#8208;known MS risk allele), as the association between IM and MS was strongest in individuals carrying both <italic toggle="yes">HLA&#8208;E*01:01</italic> and <italic toggle="yes">HLA&#8208;DRB1*15:01</italic> alleles. In contrast, individuals who lacked both alleles showed no significant increase in MS risk following IM, implying that genetic predisposition may be necessary for IM to act as a risk factor for MS.</p><p>Overall, these findings suggest that <italic toggle="yes">HLA&#8208;E*01</italic> is associated with increased MS risk in EBV&#8208;infected individuals diagnosed with IM, supporting our hypothesis and the findings by Vietzen et&#160;al. [<xref rid="ene70131-bib-0005" ref-type="bibr">5</xref>]. While previous studies focused on class II HLA alleles, such as <italic toggle="yes">HLA&#8208;DRB1*15:01</italic>, this result highlights the need to incorporate the class I <italic toggle="yes">HLA&#8208;E*01:01</italic> allele when modeling multiple MHC components of MS risk, especially in the context of prior EBV infection. Specifically, future research should aim to identify HLA allele combinations that confer the highest MS susceptibility in the presence of EBV infection, ideally using detailed data on EBNA1 levels, to better capture EBV seroconversion and IM symptomatology. If confirmed, <italic toggle="yes">HLA&#8208;E*01:01</italic> screening, along with other MS&#8208;related alleles, could improve MS risk assessment and become a key tool for targeted monitoring and early detection strategies in EBV&#8208;exposed individuals, particularly those with a history of IM diagnosis, and who could benefit from closer monitoring for early intervention. Furthermore, the interaction between <italic toggle="yes">HLA&#8208;E*01:01</italic>, IM, and MS risk suggests potential preventive and therapeutic strategies involving HLA&#8208;E&#8208;mediated immune responses to EBV.</p><p>While this study benefits from a large sample size, a long follow&#8208;up that covers an individual's lifetime, extensive confounder adjustment, and a prospective design that reduces reverse causality concerns, several limitations must be acknowledged. The main limitation relates to the collection of IM cases through diagnoses based on healthcare records or self&#8208;reporting a history of severe IM. Consequently, the prevalence of diagnosed IM cases in our cohort (0.8%) predominantly reflects cases requiring hospitalization or medical attention, which is lower than the estimated prevalence in the general population (&#8776;10%) that also includes asymptomatic and mild cases&#160;[<xref rid="ene70131-bib-0031" ref-type="bibr">31</xref>]. This limitation implies that our findings are most applicable to severe, clinically recognized IM cases, and further research is needed to explore their generalizability to EBV seroconversion and milder IM symptomatology. MS diagnoses were also derived from healthcare records and self&#8208;reports, some dating back decades, which may have introduced misclassification. Additionally, some early&#8208;onset MS cases may have been missed due to mortality before study enrollment. However, the alignment of MS prevalence in the UK Biobank with national estimates suggests accurate case identification [<xref rid="ene70131-bib-0032" ref-type="bibr">32</xref>, <xref rid="ene70131-bib-0033" ref-type="bibr">33</xref>]. Lastly, the study's predominantly white British population limits generalizability to other ethnic groups.</p></sec><sec id="ene70131-sec-0026"><title>Author Contributions</title><p>
<bold>Andrea Nova:</bold> conceptualization, methodology, software, data curation, formal analysis, visualization, writing &#8211; original draft, writing &#8211; review and editing. <bold>Davide Gentilini:</bold> writing &#8211; review and editing. <bold>Giovanni Di Caprio:</bold> conceptualization, writing &#8211; review and editing. <bold>Sonia Bourguiba&#8208;Hachemi:</bold> writing &#8211; review and editing. <bold>Nicolas Vince:</bold> writing &#8211; review and editing. <bold>Pierre&#8208;Antoine Gourraud:</bold> writing &#8211; review and editing. <bold>Luisa Bernardinelli:</bold> writing &#8211; review and editing. <bold>Teresa Fazia:</bold> conceptualization, methodology, formal analysis, writing &#8211; review and editing, supervision.</p></sec><sec sec-type="COI-statement" id="ene70131-sec-0023"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ene70131-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ENE-32-e70131-s003.txt" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ene70131-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S2.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ENE-32-e70131-s005.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ene70131-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S3.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ENE-32-e70131-s006.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ene70131-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ENE-32-e70131-s001.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ene70131-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S2.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ENE-32-e70131-s004.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ene70131-supitem-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S3.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ENE-32-e70131-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ene70131-supitem-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>
Tables S1&#8208;S5.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ENE-32-e70131-s007.xlsx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ene70131-sec-0022"><title>Acknowledgments</title><p>This research has been conducted using the UK Biobank Resource under Application Number 93731. This work uses data provided by patients and collected by the NHS as part of their care and support. Open access publishing facilitated by Universita di Pavia, as part of the Wiley &#8208; CRUI&#8208;CARE agreement.</p></ack><sec sec-type="data-availability" id="ene70131-sec-0025"><title>Data Availability Statement</title><p>Researchers may obtain access to the data used in this study upon reasonable request to the UK Biobank study team (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ukbiobank.ac.uk/" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.ukbiobank.ac.uk/</ext-link>).</p></sec><ref-list content-type="cited-references" id="ene70131-bibl-0001"><title>References</title><ref id="ene70131-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ene70131-cit-0001"><string-name name-style="western"><given-names>T.</given-names><surname>Kuhlmann</surname></string-name> and <string-name name-style="western"><given-names>J.</given-names><surname>Antel</surname></string-name>, &#8220;<article-title>Multiple Sclerosis: 2023 Update</article-title>,&#8221; <source>Free Neuropathology</source><volume>4</volume> (<year>2023</year>): <elocation-id>3</elocation-id>, <pub-id pub-id-type="doi">10.17879/freeneuropathology-2023-4675</pub-id>.<pub-id pub-id-type="pmid">37283934</pub-id><pub-id pub-id-type="pmcid">PMC10209995</pub-id></mixed-citation></ref><ref id="ene70131-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ene70131-cit-0002"><string-name name-style="western"><given-names>A.</given-names><surname>Nylander</surname></string-name> and <string-name name-style="western"><given-names>D. A.</given-names><surname>Hafler</surname></string-name>, &#8220;<article-title>Multiple Sclerosis</article-title>,&#8221; <source>Journal of Clinical Investigation</source><volume>122</volume>, no. <issue>4</issue> (<year>2012</year>): <fpage>1180</fpage>&#8211;<lpage>1188</lpage>.<pub-id pub-id-type="pmid">22466660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI58649</pub-id><pub-id pub-id-type="pmcid">PMC3314452</pub-id></mixed-citation></ref><ref id="ene70131-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ene70131-cit-0003"><string-name name-style="western"><given-names>T.</given-names><surname>Fazia</surname></string-name>, <string-name name-style="western"><given-names>G. N.</given-names><surname>Baldrighi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Nova</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Bernardinelli</surname></string-name>, &#8220;<article-title>A Systematic Review of Mendelian Randomization Studies on Multiple Sclerosis</article-title>,&#8221; <source>European Journal of Neuroscience</source><volume>58</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>3172</fpage>&#8211;<lpage>3194</lpage>.<pub-id pub-id-type="pmid">37463755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejn.16088</pub-id></mixed-citation></ref><ref id="ene70131-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ene70131-cit-0004"><string-name name-style="western"><given-names>K.</given-names><surname>Bjornevik</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cortese</surname></string-name>, <string-name name-style="western"><given-names>B. C.</given-names><surname>Healy</surname></string-name>, et&#160;al., &#8220;<article-title>Longitudinal Analysis Reveals High Prevalence of Epstein&#8208;Barr Virus Associated With Multiple Sclerosis</article-title>,&#8221; <source>Science</source><volume>375</volume>, no. <issue>6578</issue> (<year>2022</year>): <fpage>296</fpage>&#8211;<lpage>301</lpage>, <pub-id pub-id-type="doi">10.1126/science.abj8222</pub-id>.<pub-id pub-id-type="pmid">35025605</pub-id></mixed-citation></ref><ref id="ene70131-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ene70131-cit-0005"><string-name name-style="western"><given-names>H.</given-names><surname>Vietzen</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Berger</surname></string-name>, <string-name name-style="western"><given-names>L. M.</given-names><surname>K&#252;hner</surname></string-name>, et&#160;al., &#8220;<article-title>Ineffective Control of Epstein&#8208;Barr&#8208;Virus&#8208;Induced Autoimmunity Increases the Risk for Multiple Sclerosis</article-title>,&#8221; <source>Cell</source><volume>186</volume>, no. <issue>26</issue> (<year>2023</year>): <fpage>5705</fpage>&#8211;<lpage>5718</lpage>.<pub-id pub-id-type="pmid">38091993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.11.015</pub-id></mixed-citation></ref><ref id="ene70131-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ene70131-cit-0006"><string-name name-style="western"><given-names>P. J.</given-names><surname>Farrell</surname></string-name>, &#8220;<article-title>EBV and MS: The Evidence Is Growing Stronger</article-title>,&#8221; <source>Cell</source><volume>186</volume> (<year>2023</year>): <fpage>5675</fpage>&#8211;<lpage>5676</lpage>.<pub-id pub-id-type="pmid">38134873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.11.023</pub-id></mixed-citation></ref><ref id="ene70131-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ene70131-cit-0007"><string-name name-style="western"><given-names>O. G.</given-names><surname>Thomas</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bronge</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Tengvall</surname></string-name>, et&#160;al., &#8220;<article-title>Cross&#8208;Reactive EBNA1 Immunity Targets Alpha&#8208;Crystallin B and Is Associated With Multiple Sclerosis</article-title>,&#8221; <source>Science Advances</source><volume>9</volume>, no. <issue>20</issue> (<year>2023</year>): <elocation-id>eadg3032</elocation-id>.<pub-id pub-id-type="pmid">37196088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adg3032</pub-id><pub-id pub-id-type="pmcid">PMC10191428</pub-id></mixed-citation></ref><ref id="ene70131-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ene70131-cit-0008"><string-name name-style="western"><given-names>A. E.</given-names><surname>Handel</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Williamson</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Disanto</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Handunnetthi</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Giovannoni</surname></string-name>, and <string-name name-style="western"><given-names>S. V.</given-names><surname>Ramagopalan</surname></string-name>, &#8220;<article-title>An Updated Meta&#8208;Analysis of Risk of Multiple Sclerosis Following Infectious Mononucleosis</article-title>,&#8221; <source>PLoS One</source><volume>5</volume>, no. <issue>9</issue> (<year>2010</year>): <fpage>1</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0012496</pub-id><pub-id pub-id-type="pmcid">PMC2931696</pub-id><pub-id pub-id-type="pmid">20824132</pub-id></mixed-citation></ref><ref id="ene70131-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ene70131-cit-0009"><string-name name-style="western"><given-names>S. H.</given-names><surname>Loosen</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Doege</surname></string-name>, <string-name name-style="western"><given-names>S. G.</given-names><surname>Meuth</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Luedde</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kostev</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Roderburg</surname></string-name>, &#8220;<article-title>Infectious Mononucleosis Is Associated With an Increased Incidence of Multiple Sclerosis: Results From a Cohort Study of 32,116 Outpatients in Germany</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>13</volume> (<year>2022</year>): <fpage>13</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.937583</pub-id><pub-id pub-id-type="pmcid">PMC9379368</pub-id><pub-id pub-id-type="pmid">35983044</pub-id></mixed-citation></ref><ref id="ene70131-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ene70131-cit-0010"><string-name name-style="western"><given-names>E.</given-names><surname>Sundqvist</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Sundstr&#246;m</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lind&#233;n</surname></string-name>, et&#160;al., &#8220;<article-title>Epstein&#8208;Barr Virus and Multiple Sclerosis: Interaction With HLA</article-title>,&#8221; <source>Genes and Immunity</source><volume>13</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>14</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">21776012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gene.2011.42</pub-id></mixed-citation></ref><ref id="ene70131-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ene70131-cit-0011"><string-name name-style="western"><given-names>A. K.</given-names><surname>Hedstr&#246;m</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Michel</surname></string-name>, et&#160;al., &#8220;<article-title>High Levels of Epstein&#8211;Barr Virus Nuclear Antigen&#8208;1&#8208;Specific Antibodies and Infectious Mononucleosis Act Both Independently and Synergistically to Increase Multiple Sclerosis Risk</article-title>,&#8221; <source>Frontiers in Neurology</source><volume>10</volume> (<year>2020</year>): <fpage>10</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2019.01368</pub-id><pub-id pub-id-type="pmcid">PMC6992610</pub-id><pub-id pub-id-type="pmid">32038456</pub-id></mixed-citation></ref><ref id="ene70131-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ene70131-cit-0012"><string-name name-style="western"><given-names>A. K.</given-names><surname>Hedstr&#246;m</surname></string-name>, <string-name name-style="western"><given-names>I. L.</given-names><surname>Bomfim</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Barcellos</surname></string-name>, et&#160;al., &#8220;<article-title>Interaction Between Adolescent Obesity and HLA Risk Genes in the Etiology of Multiple Sclerosis</article-title>,&#8221; <source>Neurology</source><volume>82</volume>, no. <issue>10</issue> (<year>2014</year>): <fpage>865</fpage>&#8211;<lpage>872</lpage>, <pub-id pub-id-type="doi">10.1212/WNL.0000000000000203</pub-id>.<pub-id pub-id-type="pmid">24500647</pub-id><pub-id pub-id-type="pmcid">PMC3959752</pub-id></mixed-citation></ref><ref id="ene70131-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ene70131-cit-0013"><string-name name-style="western"><given-names>L.</given-names><surname>Kanevskiy</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Erokhina</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Kobyzeva</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Streltsova</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sapozhnikov</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Kovalenko</surname></string-name>, &#8220;<article-title>Dimorphism of HLA&#8208;E and Its Disease Association</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>20</volume>, no. <issue>21</issue> (<year>2019</year>): <fpage>459</fpage>.<pub-id pub-id-type="pmid">31690066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20215496</pub-id><pub-id pub-id-type="pmcid">PMC6862560</pub-id></mixed-citation></ref><ref id="ene70131-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ene70131-cit-0014"><string-name name-style="western"><given-names>E.</given-names><surname>Hosseini</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Sarraf Kazerooni</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Azarkeivan</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Sharifi</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Shahabi</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Ghasemzadeh</surname></string-name>, &#8220;<article-title>HLA&#8208;E*01:01 Allele Is Associated With Better Response to Anti&#8208;HCV Therapy While Homozygous Status for HLA&#8208;E*01:03 Allele Increases the Resistance to Anti&#8208;HCV Treatments in Frequently Transfused Thalassemia Patients</article-title>,&#8221; <source>Human Immunology</source><volume>83</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>556</fpage>&#8211;<lpage>563</lpage>.<pub-id pub-id-type="pmid">35570067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humimm.2022.04.010</pub-id></mixed-citation></ref><ref id="ene70131-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ene70131-cit-0015"><string-name name-style="western"><given-names>N. A.</given-names><surname>Patsopoulos</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Baranzini</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Santaniello</surname></string-name>, et&#160;al., &#8220;<article-title>Multiple Sclerosis Genomic Map Implicates Peripheral Immune Cells and Microglia in Susceptibility</article-title>,&#8221; <source>Science</source><volume>365</volume> (<year>2019</year>): <elocation-id>6460</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aav7188</pub-id><pub-id pub-id-type="pmcid">PMC7241648</pub-id><pub-id pub-id-type="pmid">31604244</pub-id></mixed-citation></ref><ref id="ene70131-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ene70131-cit-0016"><string-name name-style="western"><given-names>K.</given-names><surname>Rostgaard</surname></string-name>, <string-name name-style="western"><given-names>H. H.</given-names><surname>Balfour</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jarrett</surname></string-name>, et&#160;al., &#8220;<article-title>Primary Epstein&#8208;Barr Virus Infection With and Without Infectious Mononucleosis</article-title>,&#8221; <source>PLoS One</source><volume>14</volume>, no. <issue>12</issue> (<year>2019</year>): <elocation-id>5216</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0226436</pub-id><pub-id pub-id-type="pmcid">PMC6917282</pub-id><pub-id pub-id-type="pmid">31846480</pub-id></mixed-citation></ref><ref id="ene70131-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ene70131-cit-0017"><string-name name-style="western"><given-names>C.</given-names><surname>Bycroft</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Freeman</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Petkova</surname></string-name>, et&#160;al., &#8220;<article-title>The UK Biobank Resource With Deep Phenotyping and Genomic Data</article-title>,&#8221; <source>Nature</source><volume>562</volume>, no. <issue>7726</issue> (<year>2018</year>): <fpage>203</fpage>&#8211;<lpage>209</lpage>.<pub-id pub-id-type="pmid">30305743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0579-z</pub-id><pub-id pub-id-type="pmcid">PMC6786975</pub-id></mixed-citation></ref><ref id="ene70131-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ene70131-cit-0018"><string-name name-style="western"><given-names>A.</given-names><surname>Fry</surname></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Littlejohns</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sudlow</surname></string-name>, et&#160;al., &#8220;<article-title>Comparison of Sociodemographic and Health&#8208;Related Characteristics of UK Biobank Participants With Those of the General Population</article-title>,&#8221; <source>American Journal of Epidemiology</source><volume>186</volume>, no. <issue>9</issue> (<year>2017</year>): <fpage>1026</fpage>&#8211;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">28641372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwx246</pub-id><pub-id pub-id-type="pmcid">PMC5860371</pub-id></mixed-citation></ref><ref id="ene70131-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="ene70131-cit-0019"><collab collab-type="authors">UK Biobank</collab>
, &#8220;<article-title>Category 100319</article-title>,&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=100319" ext-link-type="uri">https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=100319</ext-link>.</mixed-citation></ref><ref id="ene70131-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ene70131-cit-0020"><string-name name-style="western"><given-names>L.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Hong</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xu</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>Association of HLA&#8208;E Single Nucleotide Polymorphisms With Human Myeloid Leukemia</article-title>,&#8221; <source>HLA</source><volume>103</volume>, no. <issue>4</issue> (<year>2024</year>): <elocation-id>e15440</elocation-id>.<pub-id pub-id-type="pmid">38605657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tan.15440</pub-id></mixed-citation></ref><ref id="ene70131-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="ene70131-cit-0021"><collab collab-type="authors">UK Biobank</collab>
, &#8220;<article-title>Resource 182</article-title>,&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biobank.ndph.ox.ac.uk/ukb/refer.cgi?id=182" ext-link-type="uri">https://biobank.ndph.ox.ac.uk/ukb/refer.cgi?id=182</ext-link>.</mixed-citation></ref><ref id="ene70131-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ene70131-cit-0022"><string-name name-style="western"><given-names>A.</given-names><surname>Habbestad</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Willumsen</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Aarseth</surname></string-name>, et&#160;al., &#8220;<article-title>Increasing Age of Multiple Sclerosis Onset From 1920 to 2022: A Population&#8208;Based Study</article-title>,&#8221; <source>Journal of Neurology</source><volume>271</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>1610</fpage>&#8211;<lpage>1617</lpage>.<pub-id pub-id-type="pmid">38097800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-023-12047-9</pub-id><pub-id pub-id-type="pmcid">PMC10973050</pub-id></mixed-citation></ref><ref id="ene70131-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ene70131-cit-0023"><string-name name-style="western"><given-names>A. R. T.</given-names><surname>Donders</surname></string-name>, <string-name name-style="western"><given-names>G. J. M. G.</given-names><surname>van der Heijden</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Stijnen</surname></string-name>, and <string-name name-style="western"><given-names>K. G. M.</given-names><surname>Moons</surname></string-name>, &#8220;<article-title>Review: A Gentle Introduction to Imputation of Missing Values</article-title>,&#8221; <source>Journal of Clinical Epidemiology</source><volume>59</volume>, no. <issue>10</issue> (<year>2006</year>): <fpage>1087</fpage>&#8211;<lpage>1091</lpage>.<pub-id pub-id-type="pmid">16980149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2006.01.014</pub-id></mixed-citation></ref><ref id="ene70131-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ene70131-cit-0024"><string-name name-style="western"><given-names>T. J.</given-names><surname>Van Der Weele</surname></string-name> and <string-name name-style="western"><given-names>M. J.</given-names><surname>Knol</surname></string-name>, &#8220;<article-title>A Tutorial on Interaction</article-title>,&#8221; <source>Epidemiological Methods</source><volume>3</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>33</fpage>&#8211;<lpage>72</lpage>, <pub-id pub-id-type="doi">10.1515/em-2013-0005</pub-id>.</mixed-citation></ref><ref id="ene70131-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ene70131-cit-0025"><string-name name-style="western"><given-names>M. J.</given-names><surname>Knol</surname></string-name> and <string-name name-style="western"><given-names>T. J.</given-names><surname>VanderWeele</surname></string-name>, &#8220;<article-title>Recommendations for Presenting Analyses of Effect Modification and Interaction</article-title>,&#8221; <source>International Journal of Epidemiology</source><volume>41</volume>, no. <issue>2</issue> (<year>2012</year>): <fpage>514</fpage>&#8211;<lpage>520</lpage>, <pub-id pub-id-type="doi">10.1093/ije/dyr218</pub-id>.<pub-id pub-id-type="pmid">22253321</pub-id><pub-id pub-id-type="pmcid">PMC3324457</pub-id></mixed-citation></ref><ref id="ene70131-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ene70131-cit-0026"><string-name name-style="western"><given-names>M. J.</given-names><surname>Knol</surname></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>VanderWeele</surname></string-name>, <string-name name-style="western"><given-names>R. H. H.</given-names><surname>Groenwold</surname></string-name>, <string-name name-style="western"><given-names>O. H.</given-names><surname>Klungel</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Rovers</surname></string-name>, and <string-name name-style="western"><given-names>D. E.</given-names><surname>Grobbee</surname></string-name>, &#8220;<article-title>Estimating Measures of Interaction on an Additive Scale for Preventive Exposures</article-title>,&#8221; <source>European Journal of Epidemiology</source><volume>26</volume>, no. <issue>6</issue> (<year>2011</year>): <fpage>433</fpage>&#8211;<lpage>438</lpage>, <pub-id pub-id-type="doi">10.1007/s10654-011-9554-9</pub-id>.<pub-id pub-id-type="pmid">21344323</pub-id><pub-id pub-id-type="pmcid">PMC3115067</pub-id></mixed-citation></ref><ref id="ene70131-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ene70131-cit-0027"><string-name name-style="western"><given-names>S.</given-names><surname>Knowles</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Middleton</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Cooze</surname></string-name>, et&#160;al., &#8220;<article-title>Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older&#8208;Onset Multiple Sclerosis</article-title>,&#8221; <source>Annals of Neurology</source><volume>95</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>471</fpage>&#8211;<lpage>486</lpage>.<pub-id pub-id-type="pmid">38061895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26843</pub-id></mixed-citation></ref><ref id="ene70131-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ene70131-cit-0028"><string-name name-style="western"><given-names>L.</given-names><surname>Prosperini</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lucchini</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ruggieri</surname></string-name>, et&#160;al., &#8220;<article-title>Shift of Multiple Sclerosis Onset Towards Older Age</article-title>,&#8221; <source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>93</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>1137</fpage>&#8211;<lpage>1139</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2022-329049</pub-id><pub-id pub-id-type="pmid">35477891</pub-id></mixed-citation></ref><ref id="ene70131-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ene70131-cit-0029"><string-name name-style="western"><given-names>A.</given-names><surname>Naseri</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Nasiri</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Sahraian</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Daneshvar</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Talebi</surname></string-name>, &#8220;<article-title>Clinical Features of Late&#8208;Onset Multiple Sclerosis: A Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>Multiple Sclerosis and Related Disorders</source><volume>50</volume> (<year>2021</year>): <elocation-id>102816</elocation-id>.<pub-id pub-id-type="pmid">33571792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2021.102816</pub-id></mixed-citation></ref><ref id="ene70131-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ene70131-cit-0030"><string-name name-style="western"><given-names>T. J.</given-names><surname>Vanderweele</surname></string-name>, &#8220;<article-title>Sufficient Cause Interactions and Statistical Interactions</article-title>,&#8221; <source>Epidemiology</source><volume>20</volume>, no. <issue>1</issue> (<year>2009</year>): <fpage>6</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">19234396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/EDE.0b013e31818f69e7</pub-id></mixed-citation></ref><ref id="ene70131-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ene70131-cit-0031"><string-name name-style="western"><given-names>D. H.</given-names><surname>Crawford</surname></string-name>, <string-name name-style="western"><given-names>K. F.</given-names><surname>Macsween</surname></string-name>, <string-name name-style="western"><given-names>C. D.</given-names><surname>Higgins</surname></string-name>, et&#160;al., &#8220;<article-title>A Cohort Study Among University Students: Identification of Risk Factors for Epstein&#8208;Barr Virus Seroconversion and Infectious Mononucleosis</article-title>,&#8221; <source>Clinical Infectious Diseases</source><volume>43</volume>, no. <issue>3</issue> (<year>2006</year>): <fpage>276</fpage>&#8211;<lpage>282</lpage>.<pub-id pub-id-type="pmid">16804839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/505400</pub-id></mixed-citation></ref><ref id="ene70131-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ene70131-cit-0032"><string-name name-style="western"><given-names>B. M.</given-names><surname>Jacobs</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Noyce</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bestwick</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Belete</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Giovannoni</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Dobson</surname></string-name>, &#8220;<article-title>Gene&#8208;Environment Interactions in Multiple Sclerosis: A UK Biobank Study</article-title>,&#8221; <source>Neurology Neuroimmunology &amp; Neuroinflammation</source><volume>8</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>569</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/NXI.0000000000001007</pub-id><pub-id pub-id-type="pmcid">PMC8192056</pub-id><pub-id pub-id-type="pmid">34049995</pub-id></mixed-citation></ref><ref id="ene70131-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ene70131-cit-0033"><string-name name-style="western"><given-names>A.</given-names><surname>Nova</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Di Caprio</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Bernardinelli</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Fazia</surname></string-name>, &#8220;<article-title>Genetic and Early Life Factors Influence on Time&#8208;To&#8208;Multiple Sclerosis Diagnosis: A UK Biobank Study</article-title>,&#8221; <source>Multiple Sclerosis</source><volume>30</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>994</fpage>&#8211;<lpage>1003</lpage>.<pub-id pub-id-type="pmid">38847449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13524585241257205</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>